Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Immunology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CCL1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CCL1 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native post-translational modifications. |
View CCL1 Products |
| Gene Delivery | CCL1 Promise-ORF / Lentivirus Full-length ORF for stable overexpression and microenvironment modeling. |
View CCL1 Products |
| Benchmark Ab | Anti-CCL1 Recombinant Antibody Recombinant positive control for neutralization and binding assays. |
View CCL1 Products |
| Validator | CCL1 siRNA Set For knockdown verification in functional cell-based assays. |
View CCL1 Products |
| Related Target A | CCR8 Primary GPCR receptor for CCL1; critical for Treg recruitment in the tumor microenvironment. |
View CCR8 Products |
| Related Target B | CCL2 Key homolog chemokine; essential for specificity and cross-reactivity counter-screening. |
View CCL2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Species cross-reactivity evaluation | Human, Mouse, and Cynomolgus ortholog proteins available with >95% purity verified by SDS-PAGE. |
| Subfamily counter-screening | Homolog panel (including CCL2, CCL5, and CCL8) strictly verified by mass spectrometry to ensure zero cross-contamination. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies available as positive controls. |
| False Positives in Chemotaxis | Ultra-low endotoxin control (<0.1 EU/ug) to prevent non-specific immune cell activation. |
Live CCL1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CCL1-CCR8 axis therapeutics is intensifying, with major players shifting focus from traditional systemic immunotherapy to targeted tumor-microenvironment modulation. As first-generation CCR8-targeting therapies reach the clinic, the next wave of R&D is targeting the ligand itself—CCL1—to selectively block Treg recruitment without causing systemic Treg depletion.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (mAbs) | Academic Institutions, Biotech Startups | Solid Tumors, Atopic Dermatitis | Ligand-receptor blocking assays (Need high-purity, native-glycosylated CCL1 ECD) |
| Bispecific Antibodies | Oncology-focused Biopharma | Treg-rich Hot Tumors | Dual-targeting validation (Need highly stable CCL1 and co-target proteins) |
| Small Molecule Antagonists | Global Pharma | Inflammatory Diseases, Asthma | High-throughput screening (Need sequence-verified target proteins and stable cell lines) |